Abstract: Systems and methods are provided for evicting entries from a file handle cache. In accordance with certain embodiments, a two-stage eviction process is utilized. In a first stage of the eviction process, entries in the file entry cache are analyzed and marked for eviction while a shared lock is maintained on the file handle cache. The shared lock enables the file handle cache to be concurrently accessed by a content serving system to service content requests. In a second stage of the eviction process, entries in the file handle cache that are marked for eviction are removed while an exclusive lock is maintained on the file handle cache. The exclusive lock prevents the content serving system from concurrently accessing the file handle cache to service content requests.

Abstract: Facilitating management of digital certificates is addressed. More specifically, digital certificates as well as public and private keys can be stored in a centrally accessible location and dynamically acquired from the location as needed. Additionally, binding of digital certificates and associated keys can be implicit and determined as a function of a host name provided during protocol negotiation, for example.

Abstract: Systems and methods are provided for evicting entries from a file handle cache. In accordance with certain embodiments, a two-stage eviction process is utilized. In a first stage of the eviction process, entries in the file entry cache are analyzed and marked for eviction while a shared lock is maintained on the file handle cache. The shared lock enables the file handle cache to be concurrently accessed by a content serving system to service content requests. In a second stage of the eviction process, entries in the file handle cache that are marked for eviction are removed while an exclusive lock is maintained on the file handle cache. The exclusive lock prevents the content serving system from concurrently accessing the file handle cache to service content requests.

Abstract: Facilitating management of digital certificates is addressed. More specifically, digital certificates as well as public and private keys can be stored in a centrally accessible location and dynamically acquired from the location as needed. Additionally, binding of digital certificates and associated keys can be implicit and determined as a function of a host name provided during protocol negotiation, for example.

Abstract: The present invention relates to a pharmaceutical composition for the treatment of wounds containing blood plasma or serum and a method for treating wounds effectively by applying said composition to the wound site to normalize the tissue-environment around the site.

Abstract: The present invention relates to nucleic acid probes which are derived from rRNA genes of non-virus organisms and are useful for the detection of said non-virus infectious organisms in a biological sample. In addition, the present invention relates to compositions and chips useful for the diagnosis of one or more types of infectious diseases comprising said nucleic acid probes.

Abstract: The present invention relates to methods and compositions for inhibiting scar formation on wound region. In certain embodiments, the methods include administering an alkalinization agent in combination with hyaluronic acid to a wound site to reduce the formation of scars at the wound site. Suitable alkalization agents include sodium bicarbonate, sodium hydroxide and potassium hydroxide.

Abstract: The present invention relates to a pharmaceutical composition for inhibiting scar formation on wound region which consists of hyaluronic acid and alkalization agent such as sodium bicarbonate, NaOH, and KOH.

Abstract: The present invention relates to material for diagnosing Diabetic retinopathy. More particularly, the present invention relates to Immunoglobulin A protein for diagnosing Diabetic retinopathy, kit for diagnosing Diabetic retinopathy comprising antibody against the protein and method for diagnosing Diabetic retinopathy. The present invention can be used as diagnosing Diabetic retinopathy.

Abstract: An LCD device is disclosed in which column spacers for a cell gap are arranged between gate and common lines to reduce a contact area between the column spacers and an opposing substrate, and a stable cell gap is maintained over the whole panel by reducing variation of a thickness per area of a thin film transistor (TFT) substrate corresponding to the column spacers. The LCD device includes first and second substrates facing each other, gate and data lines formed on the first substrate to cross each other, and pixel regions, a thin film transistor formed in each portion where the gate and data lines cross, common and pixel electrodes alternately formed in the pixel regions, common lines formed adjacent to the gate lines substantially parallel to the gate lines, a first column spacer formed on the second substrate corresponding to a portion between the gate line and the common line, and a liquid crystal layer filled between the first and second substrates.

Abstract: Composition for preventing the formation of new scar, e.g. myofibroblast, having BMP-7 polypeptide is disclosed. The composition for preventing the formation of scar includes an effective amount of BMP-7 (Bone Morphogenic Protein-7) polypeptide of sequence 1. The effective amount is 50 ng/ml-50 ?g/ml or 0.1 ng-1 ?g/kg by weight and the scar is a corneal scar.

Abstract: Disclosed are a method, a composition, a microarray, an antibody and a kit for diagnosis and prognosis of cancer, based on detection of deletion of the exon 3 region of G-CSF gene or levels of a mutated G-CSF protein having a deletion of an amino acid sequence corresponding to the exon 3 region, wherein the deletion of the exon 3 region of the G-CSF gene is used as a cancer biomarker.

Abstract: A liquid crystal display (LCD) device is divided into an active region and a liquid crystal margin region. The LCD includes a thin film transistor substrate that includes gate and data lines crossing each other to define pixel regions, and thin film transistors in the active region. A color filter substrate has column spacers in the active region that contact a portion corresponding to a region of the thin film transistor and the gate or data lines. The column spacers contacting the thin film transistor region provide an elastic gap between the substrates. The column spacers in the gate/data line region are separated from the color filter substrate. Other column spacers are formed in the liquid crystal margin region in a honeycomb arrangement. A liquid crystal layer is disposed between the thin film transistor and color filter substrates.

Abstract: Disclosed are a method, a composition, a microarray, an antibody and a kit for diagnosis and prognosis of cancer, based on detection of deletion of the exon 3 region of G-CSF gene or levels of a mutated G-CSF protein having a deletion of an amino acid sequence corresponding to the exon 3 region, wherein the deletion of the exon 3 region of the G-CSF gene is used as a cancer biomarker.

Abstract: Disclosed are a method, a composition, a microarray, an antibody and a kit for diagnosis and prognosis of cancer, based on detection of deletion of the exon 3 region of G-CSF gene or levels of a mutated G-CSF protein having a deletion of an amino acid sequence corresponding to the exon 3 region, wherein the deletion of the exon 3 region of the G-CSF gene is used as a cancer biomarker.

Abstract: Disclosed are a method, a composition, a microarray, an antibody and a kit for diagnosis and prognosis of cancer, based on detection of deletion of the exon 3 region of G-CSF gene or levels of a mutated G-CSF protein having a deletion of an amino acid sequence corresponding to the exon 3 region, wherein the deletion of the exon 3 region of the G-CSF gene is used as a cancer biomarker.

Abstract: Disclosed are a method, a composition, a microarray, an antibody and a kit for diagnosis and prognosis of cancer, based on detection of deletion of the exon 3 region of G-CSF gene or levels of a mutated G-CSF protein having a deletion of an amino acid sequence corresponding to the exon 3 region, wherein the deletion of the exon 3 region of the G-CSF gene is used as a cancer biomarker.